Market Intelligence, Clinical Progress, and High-Purity Reagents for Hypoxic Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CA9/CA-IX drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CA9/CA-IX ECD-Fc Fusion Protein Extracellular domain (Met38-Asp414), HEK293 Expressed (Native Glycosylation), High Purity (>95%), Endotoxin <1EU/ug, Sequence Verified. |
View CA9 Products |
| Gene Delivery | CA9/CA-IX Lentivirus Premade Particles Full-length ORF (NM_001216) for stable cell line generation, preserves native membrane conformation. |
View CA9 Products |
| Benchmark Ab | Anti-CA9 (Girentuximab Sequence) Recombinant chimeric IgG1 positive control, sequence-verified variable regions. |
View CA9 Products |
| Validator | CA9/CA-IX siRNA Set Three target-specific siRNAs for knockdown verification and assay specificity control. |
View CA9 Products |
| Related Target: CA12 | Carbonic Anhydrase XII High-homology isoform (≥90% catalytic domain identity) for selectivity counter-screening. |
View CA12 Products |
| Related Target: HIF1A | Hypoxia-Inducible Factor 1-α Upstream transcriptional regulator of CA9; pathway synergy analysis. |
View HIF1A Products |
| Related Target: CA2 | Carbonic Anhydrase II Cytosolic off-target homolog; mandatory selectivity counter-screen for small-molecule and biologic programs. |
View CA2 Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Cross-Reactivity (CA1, CA2, CA12) | Homolog panel proteins (CA2, CA12) strictly verified by mass spec for off-target liability assessment. |
| Cross-species Preclinical Translation (Cyno/Mouse) | Human, Cynomolgus (95% homology), and Mouse CA9 ortholog ECD-Fc proteins with >95% purity; sequence verified. |
| ADC Internalization Validation | Full-length CA9 Lentivirus (3rd gen) for stable cell lines preserving native glycosylation and conformation for flow cytometry-based internalization assays. |
| Lack of High-Affinity Positive Controls | Clinical benchmark antibody (Girentuximab biosimilar sequence) included as recombinant reference. |
| False Positives / Off-Target Binding | Validated siRNA included for specificity checks; shRNA lentivirus optional for stable knockdown. |
Live CA9/CA-IX R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CA9/CA-IX therapeutics has pivoted dramatically following the Phase III failure of Girentuximab (cG250) in clear cell renal cell carcinoma (ccRCC). Current R&D is dominated by next-generation modalities that overcome the limitations of naked antibodies. Antibody-Drug Conjugates (ADCs) leveraging CA9's rapid internalization kinetics—such as Bayer's BAY 79-4620—are advancing through Phase I, while CAR-T therapies targeting the hypoxic tumor microenvironment (TME) are entering preclinical development. As the field shifts toward combination strategies with checkpoint inhibitors and anti-angiogenics, the demand for stringent selectivity profiling against homologous carbonic anhydrases (particularly CA12) and robust internalization assays has become the primary technical bottleneck. First-generation therapies are reaching the clinic for ccRCC, and the next wave of R&D targets optimized internalization kinetics and minimized off-target binding to other carbonic anhydrase isoforms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Bayer (BAY 79-4620), Telix Pharmaceuticals, Academic Consortia | ccRCC, Cervical, NSCLC (hypoxic niches), Triple-negative Breast Cancer, Pancreatic Cancer | Internalization Assay (Need high-purity ECD-Fc for binding kinetics + full-length Lentivirus for cell-based uptake validation) |
| Radioligand Imaging / Therapy | Telix Pharmaceuticals, Nuclear Medicine Consortia | ccRCC, Cervical Cancer | Cell-based Binding & Dosimetry (Need full-length CA9 Lentivirus for native conformation) |
| CAR-T | Novartis, Innovent, University of Pennsylvania, Startup Biotechs | Solid Tumors, Metastatic RCC | Cell Surface Density Calibration (Need Lentivirus-transduced stable lines with physiological expression levels) |
| Small Molecule Inhibitor | SLC-0111 (Welichem), Indisulam Derivatives | Metastatic Breast Cancer, Glioblastoma | Isoform Selectivity Panel (Need purified CA9, CA12, and CA2 proteins for enzymatic inhibition assays) |
| Next-gen mAb | Chimeric variants, pH-dependent binders | ccRCC (Adjuvant) | pH-Dependent Binding ELISA (Need HEK293-expressed proteins with native glycosylation for conformational integrity) |